The prognosis in Myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) is a matter of debate. Our aim was to assess long-term outcomes of patients with MOGAD.
We retrospectively analysed clinical and paraclinical data of patients who tested positive for MOG-IgG and had clinical follow-up of at least 8 years from their first episode, from the French nationwide observatory study NOMADMUS.
Sixty-one patients (median age at onset 27, range 3-69) with median follow-up of 177 months (mean 212.8, range 98-657) were included. Among 58 patients with a relapsing course, 26.3% relapsed in the first year from onset. Of the 61 patients, 90.2% experienced at least one episode of optic neuritis. At last visit, the median EDSS was 1 (mean 2.12; range 0-7.5), 12.5% had an EDSS ≥6 and 37.5% had an EDSS ≥3. Of 51 patients with final visual acuity available, 15.7% had visual acuity ≤0.1 in at least one eye and 25.5% had visual acuity ≤0.5 in at least one eye. Bilateral blindness (visual acuity ≤0.1) was present in 5.9% of patients. Finally, 12.5% of patients presented bladder dysfunction requiring long-term urinary catheterization. No factor associated significantly with a final EDSS ≥3 or with final visual acuity ≤0.1 was found.
Overall long-term favourable outcomes were achieved in a majority of our patients, but severe impairment, in particular visual damage, was not uncommon.
About The Expert
Romain Deschamps
Julie Pique
Xavier Ayrignac
Nicolas Collongues
Bertrand Audoin
Hélène Zéphir
Jonathan Ciron
Mikael Cohen
Jennifer Aboab
Guillaume Mathey
Nathalie Derache
David Laplaud
Eric Thouvenot
Bertrand Bourre
Aurélie Ruet
Françoise Durand-Dubief
Valérie Touitou
Catherine Vignal-Clermont
Caroline Papeix
Olivier Gout
Romain Marignier
Elisabeth Maillart
References
PubMed